Bellevue Group’s AnaptysBio ANAB Stock Holding History

Bellevue Group’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-17,000	Closed	-$959K	–	213
2019 Q2	$959K	Buy	+17,000	New	+$1.22M	0.02%	141

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bellevue Group's ANAB Position: Q3 2019 in Review

Bellevue Group sold out of AnaptysBio (ANAB) in Q3 2019, closing a stake of 17,000 shares — an estimated $959K sold.

Bellevue Group first reported a position in ANAB in Q2 2019 and held it in 1 quarter. The position peaked at $959K in Q2 2019. 119 funds tracked by Wall St. Rank hold ANAB as of Q3 2019.

Bellevue Group reported no remaining AnaptysBio position as of Q3 2019 after selling out during the quarter.
Bellevue Group sold 17,000 AnaptysBio shares in Q3 2019, an estimated $959K.
Bellevue Group first reported a position in AnaptysBio in Q2 2019 and held it in 1 quarter.
Bellevue Group's AnaptysBio position peaked at $959K in Q2 2019.
119 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2019.

Based on Bellevue Group's 13F filing for Q3 2019, filed 14 Nov 2019.